Business Wire

INMOBI

12.4.2021 06:02:07 CEST | Business Wire | Press release

Share
stc pay with UM MENA and InMobi Wins Four Awards at MMA SMARTIES MENA 2020

stc pay , the leading digital wallet service in Saudi Arabia, won four awards at the MMA SMARTIES MENA 2020 , taking home a silver for COVID-19 Campaign of the Year and a total of three bronze awards in the Mobile App, Lead Generation / Direct Response / Conversions and mCommerce categories. The stc pay 'Stay at Home' campaign was the only campaign the MMA SMARTIES MENA recognized in the mCommerce and COVID-19 App categories in 2020. stc pay was awarded in numerous categories for its ‘Stay at Home’ campaign, which was co-facilitated by UM MENA and InMobi , the world’s leading independent marketing cloud.

To drive adoption of stc pay’s mobile app beginning in March 2020, especially during Eid and Ramadan, stc pay and UM utilized a three-phased approach with InMobi optimizing for specific in-app events during each phase in addition to the overarching objective of growing stc pay’s user base. Phase one of the campaign ran for most of April and highlighted how stc pay helps app users make transfers internationally while at home. Phase two of the campaign ran for the majority of May and used different creatives to highlight the ease of using stc pay from the safety of your home. Phase three was optimized towards gift box transactions, allowing users across Saudi Arabia to send Eidyah to friends and family.

The campaign exceeded the expectations of both stc pay and UM in terms of results, delivering more than 75,000 installs in a span of two months while retaining the overall Cost Per Install (CPI) figures that were well within their benchmarks. InMobi also drove over 103,000 in-app remittances for stc pay across the duration of the campaign and achieved 1.2x more gift box transfers than all other paid channels combined.

“We adapted our brand’s narrative and communication to better suit the pandemic situation during the month of Ramadan. The beauty of digital allows stc pay to act in this agile manner and give consumers what they want and need. Through our partnership with UM and InMobi we were able to effectively deliver this message to consumers and we are thrilled to have the efforts of our campaign recognized by the MMA SMARTIES,” said Abdulkarim Giraud, Digital Marketing Manager at stc pay, KSA.

“Last year was a very atypical year for all of us, requiring even more data driven planning and innovation for new solutions that would cater for rapidly changing consumer behaviors. We thank the MMA and the panel in acknowledging our collective team effort across the four categories,” said Nadeem Ibrahim, Digital Director, KSA at UM.

“2020 was a year unlike anything any of us have ever experienced before, featuring unique challenges that drove us to innovate on new solutions, dig deep into our creative reserves and forge still tighter bonds with our clients. It's quite rewarding to see our close collaboration with agency partners, innovative spirit and creativity be acknowledged by the MMA. We thank the judges and salute the inspiring competition from other brands, agencies and technology providers across the region,” said Andy Powell, VP and Managing Director, EMEA at InMobi.

For more information about the award-winning campaign, go to https://go.inmobi.net/hubfs/InMobi-stc-pay-case-study.pdf and STC Pay Video Case Study .

About stc pay

In harmony with the Kingdom’s Vision 2030 to progress and diversify digital services; stc pay, a subsidiary of stc Group, has been built to become a pioneering service of the futuristic wave that enables new endeavors and unlocks new possibilities.

We share a future vision with customers and businesses to provide new and innovative technologies and digital experiences. Using stc’s powerful network, we are able to better connect merchants with their customers through our secure digital wallet solution, stc pay, to empower both sides to complete their transactions quickly, easily, and securely.

About InMobi

InMobi drives real connections between brands and consumers by leveraging its technology platforms and exclusive access to mobile intelligence. Its Marketing Cloud creates new paths for brands to understand, identify, engage and acquire connected consumers. As a leading technology company, InMobi has been recognized on both the 2018 and 2019 CNBC Disruptor 50 lists and as one of Fast Company’s 2018 World’s Most Innovative Companies. For more information, visit inmobi.com.

About UM MENA

UM is a global media agency committed to Futureproofing our clients’ businesses for the now and the next. We leverage the transformational power of rich business analytics and real-time intelligence to maximize growth and activate the full consumer journey across content and connections. Our consultative approach and agile model, rooted in diversity, equity and belonging, drive better business outcomes for brands.

As the leading global media network owned by IPG Mediabrands and MCN Holding, ranked #1 media agency group in the MENA and #2 globally by RECMA, UM operates in over 100 countries, with more than 5,000 people. UM MENAT has operations in 12 offices and over 400 creative minds in our headquarters in Dubai, innovating on a roster of global and local clients including Coca-Cola, Emirates, Johnson & Johnson, FAB, L’Oreal, McDonalds, Reckitt, Spotify and stc.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye